<div id="readability-page-1"><p>Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) have been assigned a consensus recommendation of &#34;Moderate Buy&#34; from the seven research firms that are  covering the company, Marketbeat reports. One research analyst  has rated the stock with a sell rating, one  has issued  a hold rating, four have assigned  a buy rating and one  has given a strong buy rating to  the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $13.80.</p><div><p><span></span><span>Get <strong>Orchestra BioMed</strong> alerts:</span></p></div><p>OBIO has been the subject of several analyst reports. Chardan Capital  reaffirmed a &#34;buy&#34; rating and issued a $20.00 price objective on shares of Orchestra BioMed in a research note on Thursday, November 13th. TD Cowen initiated coverage on shares of Orchestra BioMed in a report on Wednesday, December 10th. They issued a &#34;buy&#34; rating for the company. Finally, Barclays lifted their price objective on Orchestra BioMed from $11.00 to $12.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, January 9th.</p><p><b>Check Out Our Latest Research Report on OBIO</b></p><h2>Orchestra BioMed Stock Performance</h2><p>NASDAQ:OBIO opened at $3.92 on Friday. The firm has a 50 day simple moving average of $4.16 and a 200-day simple moving average of $3.66. Orchestra BioMed has a 1-year low of $2.20 and a 1-year high of $5.42. The firm has a market cap of $221.34 million, a PE ratio of -2.15 and a beta of 0.61. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.73 and a quick ratio of 4.72. </p><h2>Institutional Investors Weigh In On Orchestra BioMed</h2><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Alyeska Investment Group L.P. bought a new stake in shares of  Orchestra BioMed during the 3rd quarter valued at $3,386,000.  Pathstone Holdings LLC acquired a new position in  Orchestra BioMed during the third quarter worth $2,495,000.  Vanguard Group Inc. increased its position in shares of  Orchestra BioMed by 28.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company's stock worth $3,675,000 after purchasing an additional 324,558 shares during the last quarter.  683 Capital Management LLC bought a new stake in shares of  Orchestra BioMed in the 4th quarter valued at about $847,000.  Finally, Marshall Wace LLP bought a new stake in  Orchestra BioMed in the 4th quarter valued at $712,000. Institutional investors and hedge funds own  53.20% of the company's stock. </p><h2>Orchestra BioMed Company Profile</h2> (Get Free Report)<p>Orchestra BioMed, Inc <span>NASDAQ: OBIO<span></span></span> is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company's research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed's pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.  </p><p>Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.</p><h2>See Also</h2><ul><li>Five stocks we like better than Orchestra BioMed</li><li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li><li>America’s 1776 happening again</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>This makes me furious</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Orchestra BioMed Right Now?</h2><p>Before you consider Orchestra BioMed, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orchestra BioMed wasn't on the list.</p><p>While Orchestra BioMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

OBIO

LABD

SBIO

<p>Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has received a consensus rating of "Moderate Buy" from seven research firms. The ratings include one sell, one hold, four buy, and one strong buy. The average price target is $13.80, with Chardan Capital setting a target of $20.00. The stock opened at $3.92, with a market cap of $221.34 million. Institutional investors own 53.20% of the company, which focuses on developing therapies for inflammatory and oncologic diseases.</p>

Market Beat

Orchestra BioMed

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bear 3X

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Consensus Rating of "Moderate Buy" by Brokerages